Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives

References

• JemalABrayFCenterMMFerlayJWardEFormanDGlobal cancer statisticsCA Cancer J Clin2011612699021296855
   PubMed Web of Science ®Google Scholar
• BerekJSCrumCFriedlanderMCancer of the ovary, fallopian tube, and peritoneumInt J Gynaecol Obstet2012119suppl 2S118S12922999503
   PubMed Web of Science ®Google Scholar
• DavisATinkerAVFriedlanderM“Platinum resistant” ovarian cancer: what is it, who to treat and how to measure benefit?Gynecol Oncol2014133362463124607285
   PubMed Web of Science ®Google Scholar
• GordonANFleagleJTGuthrieDParkinDEGoreMELacaveAJRecurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecanJ Clin Oncol200119143312332211454878
   PubMed Web of Science ®Google Scholar
• MutchDGOrlandoMGossTRandomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancerJ Clin Oncol200725192811281817602086
   PubMed Web of Science ®Google Scholar
• FriedlanderMMillwardMBellDA phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancerAnn Oncol1998912134313459932166
   PubMed Web of Science ®Google Scholar
• HoskinsPSwenertonKOral etoposide is active against platinum-resistant epithelial ovarian cancerJ Clin Oncol199412160638270985
   PubMed Web of Science ®Google Scholar
• RosePGBlessingJAMayerARHomesleyHDProlonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group StudyJ Clin Oncol19981624054109469322
   PubMed Web of Science ®Google Scholar
• Pujade-LauraineEHilpertFWeberBBevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trialJ Clin Oncol201432131302130824637997
   PubMed Web of Science ®Google Scholar
• GimbroneMALeapmanSBCotranRSFolkmanJTumor dormancy in vivo by prevention of neovascularizationJ Exp Med197213622612765043412
   PubMed Web of Science ®Google Scholar
• HanahanDFolkmanJPatterns and emerging mechanisms of the angiogenic switch during tumorigenesisCell19968633533648756718
   PubMed Web of Science ®Google Scholar
• SengerDRGalliSJDvorakAMPerruzziCAHarveyVSDvorakHFTumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluidScience198321945879839856823562
   PubMed Web of Science ®Google Scholar
• LeungDWCachianesGKuangW-JGoeddelDVFerraraNVascular endothelial growth factor is a secreted angiogenic mitogenScience19892464935130613092479986
   PubMed Web of Science ®Google Scholar
• FerraraNGerberH-PLeCouterJThe biology of VEGF and its receptorsNat Med20039666967612778165
   PubMed Web of Science ®Google Scholar
• SchmittJMateiDTargeting angiogenesis in ovarian cancerCancer Treat Rev201238427228321764518
   PubMed Web of Science ®Google Scholar
• GerberHPFerraraNPharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studiesCancer Res200565367168015705858
   PubMed Web of Science ®Google Scholar
• GerberH-PMcMurtreyAKowalskiJVascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway requirement for Flk-1/KDR activationJ Biol Chem19982734630336303439804796
   PubMed Web of Science ®Google Scholar
• YuYSatoJDMAP kinases, phosphatidylinositol 3–kinase, and p70 S6 kinase mediate the mitogenic response of human endothelial cells to vascular endothelial growth factorJ Cell Physiol1999178223524610048588
   PubMed Web of Science ®Google Scholar
• DvorakHFBrownLFDetmarMDvorakAMVascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesisAm J Pathol1995146510297538264
   PubMed Web of Science ®Google Scholar
• KraftAWeindelKOchsAVascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant diseaseCancer19998511781879921991
   PubMed Web of Science ®Google Scholar
• Abu-JawdehGMFaixJDNiloffJStrong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasmsLab Invest1996746110511158667614
   PubMed Web of Science ®Google Scholar
• YamamotoSKonishiIMandaiMExpression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levelsBr J Cancer199776912219365173
   PubMed Web of Science ®Google Scholar
• PaleyPJStaskusKAGebhardKVascular endothelial growth factor expression in early stage ovarian carcinomaCancer1997801981069210714
   PubMed Web of Science ®Google Scholar
• ShenGGhazizadehMKawanamiOPrognostic significance of vascular endothelial growth factor expression in human ovarian carcinomaBr J Cancer200083219610901370
   PubMed Web of Science ®Google Scholar
• LiLWangLZhangWCorrelation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancerAnticancer Res2004243B1973197915274387
   PubMed Web of Science ®Google Scholar
• PrestaLGChenHO’connorSJHumanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disordersCancer Res19975720459345999377574
   PubMed Web of Science ®Google Scholar
• BurgerRABradyMFBookmanMAGynecologic Oncology GroupIncorporation of bevacizumab in the primary treatment of ovarian cancerN Engl J Med2011365262473248322204724
   PubMed Web of Science ®Google Scholar
• PerrenTJSwartAMPfistererJA phase 3 trial of bevacizumab in ovarian cancerN Engl J Med2011365262484249622204725
   PubMed Web of Science ®Google Scholar
• AghajanianCBlankSVGoffBAOCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancerJ Clin Oncol201230172039204522529265
   PubMed Web of Science ®Google Scholar
• AghajanianCGoffBNycumLRWangYVHusainABlankSVFinal overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancerGynecol Oncol20151391101626271155
   PubMed Web of Science ®Google Scholar
• BurgerRASillMWMonkBJGreerBESoroskyJIPhase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group StudyJ Clin Oncol200725335165517118024863
   PubMed Web of Science ®Google Scholar
• CannistraSAMatulonisUAPensonRTPhase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancerJ Clin Oncol200725335180518618024865
   PubMed Web of Science ®Google Scholar
• GarciaAAHirteHFlemingGPhase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortiaJ Clin Oncol2008261768218165643
   PubMed Web of Science ®Google Scholar
• MatulonisUAPereiraLLiuJSequential bevacizumab and oral cyclophosphamide for recurrent ovarian cancerGynecol Oncol20121261414622487536
   PubMed Web of Science ®Google Scholar
• WenhamRMLapollaJLinHYA phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapyGynecol Oncol20131301192423623830
   PubMed Web of Science ®Google Scholar
• TillmannsTDLoweMPWalkerMSStepanskiEJSchwartzbergLSPhase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinomaGynecol Oncol2013128222122822960352
   PubMed Web of Science ®Google Scholar
• VerschraegenCFCzokSMullerCYPhase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancerAnn Oncol201223123104311022851407
   PubMed Web of Science ®Google Scholar
• KudohKTakanoMKoutaHEffects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancersGynecol Oncol2011122223323721601912
   PubMed Web of Science ®Google Scholar
• McGonigleKFMuntzHGVukyJCombined weekly topotecan and biweekly bevacizumab in women with platinum – resistant ovarian, peritoneal, or fallopian tube cancerCancer2011117163731374021815133
   PubMed Web of Science ®Google Scholar
• HagemannARNovetskyAPZighelboimIPhase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancerGynecol Oncol2013131353554024096113
   PubMed Web of Science ®Google Scholar
• LiuYRenZXuSBaiHMaNWangFLow-dose-intensity bevacizumab with weekly irinotecan for platinum- and taxanes-resistant epithelial ovarian cancerCancer Chemother Pharmacol201575364565125599660
   PubMed Web of Science ®Google Scholar
• IkedaYTakanoMOdaKWeekly administration of bevacizumab, gemcitabine, and oxaliplatin in patients with recurrent and refractory ovarian cancer: a preliminary result of 19 casesInt J Gynecol Cancer201323235536023358182
   PubMed Web of Science ®Google Scholar
• KerbelRSImproving conventional or low dose metronomic chemotherapy with targeted antiangiogenic drugsCancer Res Treat200739415015919746237
   PubMedGoogle Scholar
• KerbelRSKamenBAThe anti-angiogenic basis of metronomic chemotherapyNat Rev Cancer20044642343615170445
   PubMed Web of Science ®Google Scholar
• SistiguAViaudSChaputNBracciLProiettiEZitvogelLImmunomodulatory effects of cyclophosphamide and implementations for vaccine designSemin Immunopathol201133436938321611872
   PubMed Web of Science ®Google Scholar
• ChenCAHoCMChangMCMetronomic chemotherapy enhances antitumor effects of cancer vaccine by depleting regulatory T lymphocytes and inhibiting tumor angiogenesisMol Ther20101861233124320372107
   PubMed Web of Science ®Google Scholar
• NimeiriHSOzaAMMorganRJChicago Phase II ConsortiumPMH Phase II ConsortiumCalifornia Phase II ConsortiumEfficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II ConsortiaGynecol Oncol20081101495518423560
   PubMed Web of Science ®Google Scholar
• AzadNSPosadasEMKwitkowskiVECombination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activityJ Clin Oncol200826223709371418669456
   PubMed Web of Science ®Google Scholar
• ReidyDLChungKYTimoneyJPBevacizumab 5 mg/kg can be infused safely over 10 minutesJ Clin Oncol200725192691269517602073
   PubMed Web of Science ®Google Scholar
• Genentec [webpage on the Internet]Avastin Package Insert2015 Available from: www.gene.com/download/pdf/avastin_prescribing.pdfAccessed October 1, 2015
   Google Scholar
• RandallLMMonkBJBevacizumab toxicities and their management in ovarian cancerGynecol Oncol2010117349750420363017
   PubMed Web of Science ®Google Scholar
• IzzedineHEderhySGoldwasserFManagement of hypertension in angiogenesis inhibitor-treated patientsAnn Oncol200920580781519150949
   PubMed Web of Science ®Google Scholar
• KambaTMcDonaldDMechanisms of adverse effects of anti-VEGF therapy for cancerBr J Cancer200796121788179517519900
   PubMed Web of Science ®Google Scholar
• SteeghsNRabelinkTde KoningEGelderblomHBevacizumab-related hypertension: Search for underlying mechanismsPaper presented at: ASCO Annual Meeting ProceedingsMay 29–June 2, 2009Chicago, IL, USA
   Google Scholar
• IzzedineHAnti-VEGF cancer therapy in nephrology practiceInt J Nephrol2014201414342625210627
   PubMedGoogle Scholar
• EreminaVJeffersonJAKowalewskaJVEGF inhibition and renal thrombotic microangiopathyN Eng J Med20083581111291136
   PubMed Web of Science ®Google Scholar
• SeetRRabinsteinAClinical features and outcomes of posterior reversible encephalopathy syndrome following bevacizumab treatmentQJM20121051697521865314
   PubMed Web of Science ®Google Scholar
• HanESMonkBJWhat is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?Gynecol Oncol200710513617383545
   PubMed Web of Science ®Google Scholar
• SimpkinsFBelinsonJLRosePGAvoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screeningGynecol Oncol2007107111812317658587
   PubMed Web of Science ®Google Scholar
• ScappaticciFASkillingsJRHoldenSNArterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumabJ Natl Cancer Inst200799161232123917686822
   PubMed Web of Science ®Google Scholar
• KozloffMYoodMUBerlinJInvestigators of the BRiTE StudyClinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort studyOncologist200914986287019726453
   PubMed Web of Science ®Google Scholar
• SeewaldtVLGreerBECainJMPaclitaxel (Taxol) treatment for refractory ovarian cancer: phase II clinical trialAm J Obstet Gynecol1994170616661670 discussion 1666–16717911273
   PubMed Web of Science ®Google Scholar
• StarkDNankivellMPujade-LauraineEStandard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trialLancet Oncol201314323624323333117
   PubMed Web of Science ®Google Scholar
• MonkBJHuangHQBurgerRAPatient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group StudyGynecol Oncol2013128357357823219660
   PubMed Web of Science ®Google Scholar
• StocklerMRHilpertFFriedlanderMPatient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancerJ Clin Oncol201432131309131624687829
   PubMed Web of Science ®Google Scholar
• NumnumTMRocconiRPWhitworthJBarnesMNThe use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinomaGynecol Oncol2006102342542816797681
   PubMed Web of Science ®Google Scholar
• HamiltonCAMaxwellGLChernofskyMRBernsteinSAFarleyJHRoseGSIntraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancerGynecol Oncol2008111353053218561992
   PubMed Web of Science ®Google Scholar
• ZhaoHLiXChenDIntraperitoneal administration of cisplatin plus bevacizumab for the management of malignant ascites in ovarian epithelial cancer: results of a phase III clinical trialMed Oncol201532229225609006
   PubMed Web of Science ®Google Scholar
• ColemanRLDuskaLRRamirezPTPhase 1–2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancerLancet Oncol201112121109111721992853
   PubMed Web of Science ®Google Scholar
• TewWPColomboNRay-CoquardIIntravenous aflibercept in patients with platinum – resistant, advanced ovarian cancer: results of a randomized, double – blind, phase 2, parallel – arm studyCancer2014120333534324127346
   PubMed Web of Science ®Google Scholar
• GotliebWHAmantFAdvaniSIntravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled studyLancet Oncol201213215416222192729
   PubMed Web of Science ®Google Scholar
• MateiDSillMWLankesHAActivity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trialJ Clin Oncol2011291697521098323
   PubMed Web of Science ®Google Scholar
• BodnarLGórnasMSzczylikCSorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: a phase II studyGynecol Oncol20111231333621723597
   PubMed Web of Science ®Google Scholar
• RamasubbaiahRPerkinsSSchilderJSorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology GroupGynecol Oncol2011123349950421955480
   PubMed Web of Science ®Google Scholar
• CamposSMPensonRTMatulonisUA phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinomaGynecol Oncol2013128221522022885865
   PubMed Web of Science ®Google Scholar
• BaumannKDu BoisAMeierWA phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapyAnn Oncol20122392265227122377563
   PubMed Web of Science ®Google Scholar
• BiagiJOzaAChalchalHA phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group StudyAnn Oncol201122233534020705911
   PubMed Web of Science ®Google Scholar
• HilbergFRothGJKrssakMBIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacyCancer Res200868124774478218559524
   PubMed Web of Science ®Google Scholar
• LedermannJAHackshawAKayeSRandomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancerJ Clin Oncol201129283798380421859991
   PubMed Web of Science ®Google Scholar
• HirteHLheureuxSFlemingGA Phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a Trial of the Princess Margaret, Chicago and California phase II consortiaGynecol Oncol20151381556125895616
   PubMed Web of Science ®Google Scholar
• MatulonisUABerlinSIvyPCediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancerJ Clin Oncol200927335601560619826113
   PubMed Web of Science ®Google Scholar
• LedermannJAPerrenTJRajaFARandomized double-blind phase III trial fo cediranib (AZD 2171) in replased platinum sensitive ovarian cancer: results of the ICON6 trialPoster presented at: European Cancer CongressSept 27–Oct 1, 2013Amsterdam
   Google Scholar
• FriedlanderMHancockKCRischinDA phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancerGynecol Oncol20101191323720584542
   PubMed Web of Science ®Google Scholar
• PignataSLorussoDScambiaGMITO-11: A randomized multicenter phase II trial testing the addition of pazopanib to weekly paclitaxel in platinum-resistant or-refractory advanced ovarian cancer (AOC)Paper presented at: ASCO Annual Meeting ProceedingsMay 30–June 3, 2014Chicago, IL, USA
   Google Scholar
• EichbaumMMayerCEickhoffRThe PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancerBMC Cancer201111145322014006
   PubMed Web of Science ®Google Scholar
• MonkBJPovedaAVergoteIAnti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trialLancet Oncol201415879980824950985
   PubMed Web of Science ®Google Scholar
• FerrissJSJavaJJBookmanMAAscites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG studyGynecol Oncol20151391172226216729
   PubMed Web of Science ®Google Scholar
• BennounaJSastreJArnoldDML18147 Study InvestigatorsContinuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trialLancet Oncol2013141293723168366
   PubMed Web of Science ®Google Scholar
• BackesFJRichardsonDLMcCannGAShould bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?Int J Gynecol Cancer201323583383823640292
   PubMed Web of Science ®Google Scholar
• RandallLMSillMWBurgerRAMonkBJBueningBSoroskyJIPredictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trialGynecol Oncol2012124356356822138229
   PubMed Web of Science ®Google Scholar
• GelmonKATischkowitzMMackayHOlaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised studyLancet Oncol201112985286121862407
   PubMed Web of Science ®Google Scholar
• PovedaAMSelleFHilpertFBevacizumab combined with weekly paclitaxel, Pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomized phase III AURELIA trialJ Clin Oncol Epub2015817
   Web of Science ®Google Scholar